ESG Report

Overview

The report highlights Emergent's FDA approval and OTC launch of NARCAN Nasal Spray, FDA approval of CYFENDUS, and continued public-health product development. It describes a new 2023 materiality assessment supported by external stakeholders and identifies priority areas including climate impact, occupational health and safety, and ESG oversight. The environmental section reports Scope 1 and Scope 2 emissions, energy, and onsite water usage. Social highlights include employee development, hybrid work, wellness programs, and diversity and inclusion initiatives.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: Ends 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services